Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.
'We are thrilled to have such a distinguished oligonucleotide leader as Art Levin join our SAB,' said Stefan Lutz, PhD, Senior Vice President of Research at Codexis. 'With extensive experience in the development of numerous oligonucleotides, including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials, Art will provide invaluable guidance as we continue on our growth trajectory with the ECO Synthesis platform.'
Dr. Levin added, 'I am excited to partner with Codexis as it expands the possibility of RNAi therapeutics through its groundbreaking enzymatic technologies. As someone who has been in the oligonucleotide business for decades, it is exciting to see momentum for the space increasing so drastically. I look forward to working with the management team and SAB to help usher Codexis through this next phase of growth.'
In addition to his role on the Board of Directors, Dr. Levin previously held the positions of Distinguished Scientist, Strategic Leader and Chief Scientific Officer at Avidity. Dr. Levin is a highly regarded key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. Prior to joining Avidity, Dr. Levin was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharmaceuticals. He has published more than 100 scientific articles and has authored several of the most cited reviews in the field. In addition to Codexis, he serves on the scientific advisory boards of multiple institutions. Dr. Levin received a doctorate in toxicology from the University of Rochester and holds a bachelor's degree in biology from Muhlenberg College.
About the Codexis Strategic Advisory Board
Codexis' Strategic Advisory Board (SAB) was established in 2023 and is comprised of experts across oligonucleotide synthesis, manufacturing and commercialization. The SAB plays a pivotal role in guiding the Company's strategic direction and offers valuable insights to inform the continued development of the ECO Synthesis™ manufacturing platform. Current members include John Maraganore, PhD, founder and former Chief Executive Officer of Alnylam Pharmaceuticals; Masad Damha, PhD, Distinguished James McGill Professor at McGill University; Jim Lalonde, PhD, biotechnology consultant for start-up companies in enzyme engineering and former Senior Vice President of Research and Development at Codexis; and Carole Cobb, MBA, biotechnology consultant and former Chief Operating Officer at GreenLight Biosciences. More information about Codexis' SAB can be found on the About Us section of the Company's corporate website, located here.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'suggest,' 'target,' 'on track,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis' dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis' business if its customers' products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis' products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on February 28, 2024 and in Codexis' Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption 'Risk Factors,' and in Codexis' other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(650) 421-8205media@codexis.com
A photo accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/e3137aaa-14c6-4e44-b71a-cb4b8bc4e4cbSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
eXp Realty Dominates 2025 RealTrends Rankings With 757 Agents and Teams Honored
40 eXp Realty agents and teams break into the elite 'The Thousand' list, and the firm claims #1 spot for transactions nationwideBELLINGHAM, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that a record-breaking 757 of its agents and teams have been named among the top real estate professionals in the country, according to the 2025 RealTrends Verified America's Best List. With fewer than 0.1% of agents qualifying nationwide, inclusion in the RealTrends rankings is a rare achievement that reflects exceptional production and service. Adding to the celebration, eXp Realty also ranked as the: #1 Brokerage in the U.S. by Transaction Sides #3 Brokerage in the U.S. by Sales Volume These accolades underscore eXp's continued dominance in the real estate space and its commitment to supporting agents through a robust cloud-based platform, best-in-class tools, and unparalleled collaboration opportunities. 'At eXp Realty, our agents are our greatest asset. Seeing 757 of our professionals earn recognition on the RealTrends lists is both humbling and energizing,' said Leo Pareja, CEO of eXp Realty. 'This success is a direct result of our commitment to providing agents with the tools, model, and culture they need to thrive. We are building something extraordinary, and this achievement is a powerful testament to the strength of our community.' With a mission to empower agents to build better businesses, eXp Realty continues to redefine what's possible in real estate, offering top-tier financial incentives, cutting-edge technology, and a globally connected network – all of which contribute to driving results for clients and professionals alike. About eXp World Holdings, Inc. eXp World Holdings, Inc. (Nasdaq: EXPI) (the 'Company') is the holding company for eXp Realty® and SUCCESS® Enterprises. eXp Realty is the largest independent real estate brokerage in the world, with over 81,000 agents across 27 countries. As a cloud-based, agent-centric brokerage, eXp Realty provides real estate agents industry-leading commission splits, revenue share, equity ownership opportunities, and a global network that empowers agents to build thriving businesses. For more information about eXp World Holdings, Inc., visit: SUCCESS® Enterprises, anchored by SUCCESS® magazine, has been a trusted name in personal and professional development since 1897. As part of the eXp ecosystem, it offers agents access to valuable resources to enhance their skills, grow their businesses, and achieve long-term success. For more information about SUCCESS, visit Safe Harbor and Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's and its management's current expectations but involve known and unknown risks and uncertainties that could impact actual results materially. These statements include, but are not limited to, statements regarding the anticipated success of agents or teams joining eXp Realty, future production goals or volume projections, and participation in or benefits derived from the Company's platform, tools, compensation model, or equity programs. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include real estate market fluctuations, changes in agent retention or recruitment, the Company's ability to expand successfully in international markets, competitive pressures, regulatory changes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including but not limited to the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. We do not undertake any obligation to update these statements except as required by law. Media Relations Contact:eXp World Holdings, Investor Relations Contact:Denise Garciainvestors@ A photo accompanying this announcement is available at
Yahoo
20 minutes ago
- Yahoo
GenAI Growth, Creative Cloud Pricing in Focus as Adobe Reports Q2
Adobe (NASDAQ:ADBE) is set to release its fiscal Q2 results on Thursday after markets close, and analysts say the spotlight will be squarely on the company's generative AI roadmap and competitive strategy. Morgan Stanley believes investor worries over Adobe's positioning in the AI space have contributed to the stock underperforming large-cap software peers by roughly 15 percentage points over the past three months. In a note Tuesday, analyst Keith Weiss said low expectations paired with potential gains in annual recurring revenue for Adobe's Digital Media business create a favorable risk-reward setup. The firm rates the stock Overweight with a $510 price target. Weiss also pointed to Adobe's push for innovation at the high end of its product line and more flexible pricing for smaller customers as key to boosting growth. Jefferies echoed that optimism, highlighting Adobe's 7% price hike for Creative Cloud renewals starting June 17. Analyst Brent Thill said the move should help offset headwinds from prior pricing changes and potentially lift 2026 results. Jefferies maintains a Buy rating and a $590 price target. Consensus estimates call for adjusted earnings of $4.97 per share on revenue of $5.8 billion. That compares with $5.08 in adjusted EPS and $5.71 billion in revenue from the previous quarter. Jefferies also flagged currency movements as a potential boost to revenue, estimating a 1 percentage point tailwind compared with current expectations of a neutral to slight headwind. This article first appeared on GuruFocus.
Yahoo
21 minutes ago
- Yahoo
Be Sure To Check Out Nasdaq, Inc. (NASDAQ:NDAQ) Before It Goes Ex-Dividend
Readers hoping to buy Nasdaq, Inc. (NASDAQ:NDAQ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least one business day to settle. This means that investors who purchase Nasdaq's shares on or after the 13th of June will not receive the dividend, which will be paid on the 27th of June. The company's next dividend payment will be US$0.27 per share, and in the last 12 months, the company paid a total of US$1.08 per share. Based on the last year's worth of payments, Nasdaq has a trailing yield of 1.3% on the current stock price of US$85.65. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to investigate whether Nasdaq can afford its dividend, and if the dividend could grow. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. That's why it's good to see Nasdaq paying out a modest 43% of its earnings. Generally speaking, the lower a company's payout ratios, the more resilient its dividend usually is. Check out our latest analysis for Nasdaq Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're encouraged by the steady growth at Nasdaq, with earnings per share up 7.3% on average over the last five years. Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. In the last 10 years, Nasdaq has lifted its dividend by approximately 18% a year on average. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders. Should investors buy Nasdaq for the upcoming dividend? It has been growing its earnings per share somewhat in recent years, although it reinvests more than half its earnings in the business, which could suggest there are some growth projects that have not yet reached fruition. We think this is a pretty attractive combination, and would be interested in investigating Nasdaq more closely. While it's tempting to invest in Nasdaq for the dividends alone, you should always be mindful of the risks involved. Case in point: We've spotted 1 warning sign for Nasdaq you should be aware of. If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
